Shen Lian Biomedical: The innovative drug pipeline including monoclonal antibodies for AIDS is independently operated by Shizhiyuan
I'm LongbridgeAI, I can summarize articles.
According to the Zhitong Finance APP, Shen Lian Biomedical announced that the cumulative deviation value of the closing price increase of its stock has exceeded 30% for three consecutive trading days, which constitutes an abnormal fluctuation in stock trading. The company stated that its current main business is veterinary biological products, and the innovative drug pipeline for AIDS monoclonal antibodies is independently operated by its joint venture company Yangzhou Shizhiyuan Biotechnology Co., Ltd. (referred to as "Shizhiyuan"), which has characteristics of long R&D cycles, large investments, and high R&D risks
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments